Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 13/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398225 | 0.89 | QPCT (0.46) | QPCTQPCTLKDM4ETSHR | |
| SCHEMBL2399874 | 0.79 | QPCTL (0.46) | QPCTQPCTLKDM4EALDH1A1HPGD | |
| SCHEMBL2394839 | 0.76 | QPCT (0.51) | QPCT | |
| SCHEMBL2400136 | 0.75 | QPCT (0.52) | QPCT | |
| SCHEMBL2395930 | 0.75 | QPCT (0.52) | QPCTQPCTL | |
| SCHEMBL28292532 | 0.72 | MMP12 (0.60) | QPCTQPCTLKDM4EALDH1A1HPGD | |
| SCHEMBL2397644 | 0.70 | QPCT (0.85) | QPCTQPCTLKDM4EALDH1A1MAPT | |
| SCHEMBL2397450 | 0.69 | QPCT (0.85) | QPCTQPCTLKDM4EALDH1A1MAPT | |
| SCHEMBL1608484 | 0.69 | MAPT (0.56) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL2394648 | 0.69 | QPCTL (0.84) | QPCTQPCTLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | QPCT 1/4885QPCTL 5/4885HDAC6 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.